Proxy Votes Now

Home › Upcoming votes › REVIVA PHARMACEUTICALS HOLDINGS, INC.

REVIVA PHARMACEUTICALS HOLDINGS, INC. Annual Meeting December 18, 2026: What's on the Ballot

Say on paySignificant dissent last year

Prior-year votes at REVIVA PHARMACEUTICALS HOLDINGS, INC. → 2025-2026 season, in the search

The deadline as the proxy statement states it: “voting facilities are available now and will be available 24 hours a day until 11:59 p.m., Eastern Time, on December 17, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.

Read the proxy statement on EDGAR

Proxy summary

Summary, checked against the proxy statement. Each point is backed by a passage of the filing, shown under the point; figures under “Last year’s votes” come from the company’s Form 8-K. Read the proxy statement before relying on it.

Annual meeting: five directors, auditor ratification, say-on-pay, a reverse stock split proposal and an adjournment proposal, all with a board recommendation of FOR.

Key points

What changed from last year

Last year’s votes

What’s on the ballot

Ballot read from the proxy statement and checked. As listed in REVIVA PHARMACEUTICALS HOLDINGS, INC.’s proxy statement, with the board’s recommendation on each item.

#ItemProposed byBoard recommendsLast year (same kind of item)
1 Election of directors
Director election
Board For 5 nominees; support 70% to 83%
2 Ratification of Baker Tilly US, LLP as auditor
Auditor
Board For 95% support
3 Advisory vote on executive compensation
Say on pay
Board For 71% support
4 Reverse stock split charter amendment Board For —
5 Adjournment of the Annual Meeting
Adjournment
Board For —

Last year’s official results

From REVIVA PHARMACEUTICALS HOLDINGS, INC.’s Form 8-K, filed December 23, 2025, for the meeting held December 18, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.

ItemSupport (of votes cast)Reported outcome
Elect Director: Laxminarayan Bhat83%—
Elect Director: Parag Saxena71%—
Elect Director: Richard Margolin76%—
Elect Director: Purav Patel70%—
Elect Director: Les Funtleyder76%—
2. Proposal to ratify the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the Company'95%Approved
3. Proposal to approve, on an advisory basis, the executive compensation of the Company's named executive officers71%Approved
4. Proposal to approve the Increase in Authorized Charter Amendment to increase the Company's authorized shares of Common Stock from 315,00062%Approved
5. Proposal to approve the Reverse Split Charter Amendment to effect a reverse stock split of the Company's issued shares of Common Stock, a68%Approved

Filings for this meeting

About this page

The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.